Tissue Regenix Group plc

Device Transactions Financing by device companies in the third quarter of 2017 totaled $2.38 billion, double Q2's $1.2 billion. ( See Exhibit 1. ) Debt again this quarter made up most of the aggregate

Anthony Odell, who has been leading Tissue Regenix Group PLC for nearly a decade, is stepping down as CEO. His departure, announced Oct. 18, comes two months after he oversaw the closing of the re

Tissue Regenix Group PLC (TRX) is acquiring CellRight Technologies , a US bone regeneration technology specialist, in a deal worth up to $30m. The acquisition is the first for Leeds, UK-based TRX a

Several smaller, venture-backed medtech players initiated new clinical trials in July, as recorded by Informa's Meddevicetracker . Among the notable studies started last month are Bigfoot Biomedi